Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2008
Business Overview: NAI is a formulator, manufacturer, and marketer of nutritional supplements. Its primary business is private label contract manufacturing for companies marketing vitamins, minerals, and herbs. It also markets its own branded products under the "Pathway to Healing" line. Operations are located in California, USA, and Manno, Switzerland.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 |
|---|---|---|
| Total Net Sales | $93.0 million | $97.1 million |
| Net Sales (Continuing Ops) | $81.8 million | $86.6 million |
| Net Loss | $(0.4) million | $(5.3) million |
| Income from Continuing Ops | $0.9 million | $2.7 million |
| Loss from Discontinued Ops | $(1.3) million | $(8.0) million |
| Gross Margin (Continuing Ops) | 15.8% | 18.2% |
| Operating Income (Continuing Ops) | $1.1 million | $3.8 million |
| Cash and Cash Equivalents | $3.5 million | $4.1 million |
| Total Debt | $2.7 million | $4.6 million |
| Working Capital Line Available | $7.5 million | $12.0 million (reduced) |
Material Changes vs. Prior Period
- Revenue Decline: Total net sales decreased 4.2% to $93.0 million. Continuing operations sales dropped 5.6% due to a 3.6% decline in private label manufacturing (lower volumes from a major customer) and a 33.1% drop in branded products sales.
- Discontinued Operations: The legacy Real Health Laboratories (RHL) business was reclassified as discontinued operations. This segment generated a net loss of $1.3 million in 2008 compared to $8.0 million in 2007 (which included a $7.0 million goodwill impairment charge).
- Asset Sale: On August 4, 2008, NAI sold the "As We Change" catalog and internet business assets for $2.3 million (including post-closing adjustments).
- Profitability: Operating income from continuing operations fell 71% to $1.1 million, driven by lower sales and increased costs related to GMP compliance and quality assurance.
- Customer Concentration: Revenue concentration increased. The two largest customers (NSA International and Mannatech) accounted for 83% of continuing operations sales in 2008, up from 79% in 2007.
Guidance, Outlook, and Risks
- Strategic Shift: Management is narrowing its branded product focus to the "Pathway to Healing" line and intends to sell the remaining legacy RHL business in fiscal 2009.
- Exit Costs: NAI anticipates incurring $1.2 million to $1.5 million in severance and exit costs related to the RHL divestiture and operational consolidation in the first quarter of fiscal 2009.
- Covenant Compliance: The company failed to meet quarterly and annual net income covenants under its credit facility for fiscal 2008. While the lender waived default rights as of June 30, 2008, NAI expects to miss the covenant again in Q1 2009 due to exit costs and is seeking a waiver. Consequently, all long-term debt has been reclassified as current.
- Key Risks:
- Customer Dependency: Loss of NSA International (49% of sales) or Mannatech (34% of sales) would materially harm operations.
- Regulatory: Compliance with new FDA Good Manufacturing Practices (GMP) requires significant investment and adherence by June 2009.
- Liquidity: Reliance on a credit facility with reduced borrowing capacity and potential covenant waivers.
Investor Verification Checklist
- Covenant Waivers: Verify if the lender has granted a waiver for the expected Q1 2009 covenant violation to avoid debt acceleration.
- RHL Divestiture: Monitor the timeline and terms for the sale of the remaining legacy RHL business operations.
- Customer Retention: Assess the stability of relationships with NSA International and Mannatech, given their combined 83% revenue share.
- Exit Cost Realization: Track the actual severance and consolidation costs against the estimated $1.2M–$1.5M range.
- Branded Product Performance: Evaluate the recovery or decline of the "Pathway to Healing" product line following the cessation of Dr. Cherry's television program.